Caladrius Biosciences to Participate at Upcoming February Conferences
February 03 2020 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announced today that David
J. Mazzo, PhD, President and Chief Executive Officer of the
Caladrius, will present a company overview at the following
conferences in February:
LSX World Congress 2020
|
Date: |
Wednesday, February 5, 2020 |
| Time: |
12:30 p.m. (GMT) |
| Track: |
Inv€$table Biotech |
| Venue: |
133 Houndsditch, Liverpool Street
in London, UK |
2020 BIO CEO & Investor Conference
|
Date: |
Monday, February 10, 2020 |
| Time: |
9:45 a.m. (EST) |
| Location: |
Wilder room |
| Venue: |
New York Marriott Marquis in New
York, NY |
Noble Capital Markets’ Sixteenth Annual Investor
Conference
|
Date: |
Tuesday, February 18, 2020 |
| Time: |
11:30 a.m. (EST) |
| Location: |
Terrace Ballroom B |
| Venue: |
The Hard Rock Hotel & Casino
in Hollywood, FL |
| Webcast: |
www.caladrius.com/investors/news-events/events/ |
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, a Phase 3 ready clinical program in no
option refractory disabling angina and recipient of a RMAT
designation in the U.S.A. For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024
